Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979412453> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2979412453 abstract "Abstract Background Although, FOLFIRINOX and nab-paclitaxel plus gemcitabine showed survival benefit in patients with advanced pancreatic cancer (APC) , there is no standard chemotherapy for APC after nab paclitaxel plus gemcitabine failure. Methods We retrospectively evaluated the efficacy and safety of FOLFIRINOX as salvage treatment in patients with APC refractory or intolerant to nab paclitaxel plus gemcitabine. Results Between July 2014 and October 2018, 23 patients received FOLFIRINOX after failure to nab-paclitaxel plus gemcitabine. The overall response rate (RR) was 23% and the disease control rate (DCR) was 68%. Median progression free survival (PFS) was 5.3 months (95% confidence interval (CI) 2.5-8.9 months ) and median overall survival (OS) was 12.1 months (95%CI : 4.0-14.2 months), 12 patients received FOLFIRINOX and 11 patients received modified FOLFIRINOX. In FOLFIRINOX group, RR was 9%, DCR was 73%, PFS was 5.3 months, and OS was 6.9 months. In modified FOLFORINOX group, RR was 23%, DCR was 64%, PFS was 4.3 months, and OS was 12.8 months. There was no significantly difference between both groups. And there was no significantly difference between both groups. Conclusion Second line chemotherapy with the FOLFIRINOX has a potential activity and is tolerable for APC who were failure to gemcitabine plus nab-paclitaxel." @default.
- W2979412453 created "2019-10-18" @default.
- W2979412453 creator A5003272799 @default.
- W2979412453 creator A5015480315 @default.
- W2979412453 creator A5016344571 @default.
- W2979412453 creator A5039675116 @default.
- W2979412453 creator A5043256743 @default.
- W2979412453 creator A5052222940 @default.
- W2979412453 creator A5072827290 @default.
- W2979412453 creator A5074800153 @default.
- W2979412453 creator A5087090379 @default.
- W2979412453 creator A5087517300 @default.
- W2979412453 date "2019-10-01" @default.
- W2979412453 modified "2023-09-23" @default.
- W2979412453 title "FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis" @default.
- W2979412453 doi "https://doi.org/10.1093/annonc/mdz343.057" @default.
- W2979412453 hasPublicationYear "2019" @default.
- W2979412453 type Work @default.
- W2979412453 sameAs 2979412453 @default.
- W2979412453 citedByCount "0" @default.
- W2979412453 crossrefType "journal-article" @default.
- W2979412453 hasAuthorship W2979412453A5003272799 @default.
- W2979412453 hasAuthorship W2979412453A5015480315 @default.
- W2979412453 hasAuthorship W2979412453A5016344571 @default.
- W2979412453 hasAuthorship W2979412453A5039675116 @default.
- W2979412453 hasAuthorship W2979412453A5043256743 @default.
- W2979412453 hasAuthorship W2979412453A5052222940 @default.
- W2979412453 hasAuthorship W2979412453A5072827290 @default.
- W2979412453 hasAuthorship W2979412453A5074800153 @default.
- W2979412453 hasAuthorship W2979412453A5087090379 @default.
- W2979412453 hasAuthorship W2979412453A5087517300 @default.
- W2979412453 hasConcept C121608353 @default.
- W2979412453 hasConcept C126322002 @default.
- W2979412453 hasConcept C141071460 @default.
- W2979412453 hasConcept C143998085 @default.
- W2979412453 hasConcept C2776694085 @default.
- W2979412453 hasConcept C2777148230 @default.
- W2979412453 hasConcept C2777292972 @default.
- W2979412453 hasConcept C2780210213 @default.
- W2979412453 hasConcept C2780258809 @default.
- W2979412453 hasConcept C2780259306 @default.
- W2979412453 hasConcept C526805850 @default.
- W2979412453 hasConcept C71924100 @default.
- W2979412453 hasConceptScore W2979412453C121608353 @default.
- W2979412453 hasConceptScore W2979412453C126322002 @default.
- W2979412453 hasConceptScore W2979412453C141071460 @default.
- W2979412453 hasConceptScore W2979412453C143998085 @default.
- W2979412453 hasConceptScore W2979412453C2776694085 @default.
- W2979412453 hasConceptScore W2979412453C2777148230 @default.
- W2979412453 hasConceptScore W2979412453C2777292972 @default.
- W2979412453 hasConceptScore W2979412453C2780210213 @default.
- W2979412453 hasConceptScore W2979412453C2780258809 @default.
- W2979412453 hasConceptScore W2979412453C2780259306 @default.
- W2979412453 hasConceptScore W2979412453C526805850 @default.
- W2979412453 hasConceptScore W2979412453C71924100 @default.
- W2979412453 hasLocation W29794124531 @default.
- W2979412453 hasOpenAccess W2979412453 @default.
- W2979412453 hasPrimaryLocation W29794124531 @default.
- W2979412453 hasRelatedWork W10745580 @default.
- W2979412453 hasRelatedWork W12670419 @default.
- W2979412453 hasRelatedWork W13943329 @default.
- W2979412453 hasRelatedWork W17733091 @default.
- W2979412453 hasRelatedWork W2544042 @default.
- W2979412453 hasRelatedWork W4018899 @default.
- W2979412453 hasRelatedWork W415001 @default.
- W2979412453 hasRelatedWork W6817586 @default.
- W2979412453 hasRelatedWork W8750365 @default.
- W2979412453 hasRelatedWork W9134849 @default.
- W2979412453 isParatext "false" @default.
- W2979412453 isRetracted "false" @default.
- W2979412453 magId "2979412453" @default.
- W2979412453 workType "article" @default.